Total cholesterol 366 and LDL 286: what the data say

Total cholesterol 366: the case that reopens what real risk is

A total cholesterol of 366 mg/dL with an LDL of 286 leaves no room for half-measures: it's either a time bomb or statistical noise. The case that has fueled hundreds of messages starts with a 50-year-old man, 102 kilos and 1.84 meters, who had been strength training and bodybuilding for decades without pharmacological aids, with a diet free of processed foods and sugars but generous in fatty red meat, whole eggs and butter.

Triglycerides, however, were at 82 mg/dL. HDL at 63. And urea at 62. Context matters: two months of almost extreme sedentary lifestyle after a foot fracture that left him in a cast on the couch. The question he asked—whether he was going to die or if nothing was wrong—received two opposite answers with identical certainty. That's where the problem starts: no one disputes the numbers, what's disputed is what they miccionan.

What does a total cholesterol of 366 mg/dL imply?

For the majority clinical criteria, such a figure places the patient at high cardiovascular risk and justifies pharmacological intervention. The affected person himself later received a prescription for rosuvastatin 10 mg, with trinc-up blood tests in March. So far, predictable.

The interesting thing is that the panel is not homogeneous. With triglycerides at 82 and HDL at 63, the pattern doesn't fit classic metabolic syndrome, where skyrocketing triglycerides and plummeting HDL accompany high LDL. That mismatch is what fuels the doubt.

On another different blood test—total 225, HDL 41, LDL 147 and triglycerides 185—a breakdown of ratios circulates that illustrates well what is looked at when one wants to go beyond the total: remnant cholesterol of 37 mg/dL when desirable would be below 20, an LDL/HDL ratio of 3.5 versus a threshold of 3, and a TG/HDL of 4.5, clearly high. Remnant and ratios refine the prognosis; the total, in isolation, says little.

Weight: 8 kilos, 12 or more than 20 depending on the scale

The second front was weight. The protagonist acknowledged about 8 kilos of excess and then raised the margin to 12, appealing to his bone structure and muscle mass accumulated over decades in the gym. The responses were far less indulgent: some assigned him more than 20 kilos of excess and some even spoke of 28.

The exchange reveals a real disagreement about how body fat is measured in a muscular person. A participant 1.86 meters tall and 159 kilos confessed an LDL cholesterol of 478 mg/dL and a doctor with the prescription ready. Another, same height as the initial case and ten kilos less, said his doctor still asked him to lose another ten. The scale, like cholesterol, doesn't settle the debate either.

Randle cycle, glucose and the war between diets

Here the matter drifted into a deep nutritional discussion, with two currents clashing for much of the conversation. One defends that the problem is not animal fat but excess carbohydrates: the Randle cycle is invoked, that mechanism by which one macronutrient inhibits the use of the other, and it is argued that sugar and rice—including brown—play in the same league due to the insulin spike they cause.

Along those lines, it is stated that lipolysis stops from about 5 units and autophagy from 7 or 8, and that without accessing one's own fat reserves it is impossible to improve the lipid profile. The argument of blood glucose is added, whose excess sticks to other molecules through a Maillard-type reaction and denatures them, according to this current.

Opposite, the plant-based thesis. It is recalled that one can be vegan and have high cholesterol, and it is stressed that triglycerides are the marker that truly matters in cardiovascular risk. The discussion got tangled in whether humans are facultative carnivores or herbivores with nuances, a dead end where no one gave an inch.

The scientific citation thrown on the table was a study published in BMJ Open on primary prevention patients without diabetes and without statins: the lowest long-term mortality risk appeared in a much broader LDL range than guidelines recommend, between 100 and 189 mg/dL. Ancel Keys' Seven Countries study was also brought up and the accusation, repeated so many times, that it left out countries that contradicted his thesis. Some maintain that it conditioned fifty years of nutritional policy.

Lipoprotein(a) and remnant: the markers that change the picture

While some discussed diets, others went looking for markers that rarely come up in daily conversation. The most striking: a blood test with total cholesterol 229, HDL 64, LDL 149.4, triglycerides 78 and an atherogenic index of 3.58, which seemed apparently controlled. Until lipoprotein(a) appeared: 187.8 mg/dL with a reference below 30. That report labels it as double the risk.

Some recommended requesting that test routinely in the next blood test, because the cholesterol circulating in the arteries has some blood and not everything is explained by LDL. Another case added apolipoprotein B at 159, read as a sign of small LDL particles, the ones that deposit in the arterial wall. The diagnosis becomes finer, and also more uncomfortable, when these pieces are added.

Rosuvastatin 10 mg, red rice and side effects

The practical outcome of the initial case was a mild prescription: 10 mg of rosuvastatin and review in March. After a new analysis in which everything came out correct—tumor markers, urine, blood, triglycerides and urea—except cholesterol, which remained high despite continuing to train and living in the countryside, with the consumption of red meat, butter and eggs intact.

The conversation about drugs was the harshest. A case with apolipoprotein B at 159 explained that he had given up at 54 and had started with 20 mg, at a cost of 7.95 euros for 28 tablets. Against that, testimonies of adverse effects: severe insomnia in a week, serious muscle pain, feeling of having messed up the hormonal axis after trying three different medications. And an intermediate path: red rice extract, which contains natural statins, with which a drop from 270 to 198 was reported, accompanied by the advice to supplement coenzyme Q10.

The conclusion that some defend is that cholesterol serves functions and that lowering it without looking at the whole picture is a mistake. Other participants defend the opposite. And between one thing and another, the 50-year-old patient waits until March.

With these ingredients, it is reasonable to anticipate that the next blood test will say more than this debate: whether low-dose rosuvastatin moves the number and whether the rest of the panel holds up. What will not be resolved is the underlying question, the one that confronts those who look at the total and those who look at the ratios. Both will continue to have tables, studies and cases that prove them right. That's what it's like to argue with someone else's body.